The department offers a unique environment for research and training that combines Systems Physiology with Chemical Biology in a synergistic and highly collaborative atmosphere. Learn more
Chemical Biology and Physiology Summer Undergraduate Research Program (CBP-SURP)
Applications are now being accepted for the 2018 program, due March 23rd.
The first Chemical Biology and Physiology Summer Undergraduate Research Program (CBP-SURP) was a success! Undergraduate students from various universities participated in an 8-week summer program designed to provide undergraduates research opportunities at the interface of chemistry, biology and physiology in the health sciences.
Student participants, home university and OHSU summer labs:
Ashley Person, Whitman College, Michael Cohen
Eda Shi, Indiana Univ., Carsten Schultz
Joseph Pingleton, George Fox Univ., Xiangshu Xiao
Heidi Funderburgh, George Fox Univ., Oline Ronnekleiv
Louis Sumrall, Portland State Univ., Catherine Morgans
Emma Eikermann, Lewis and Clark College, Sue Aicher
New hope for treating a rare genetic disorder
An idea that flickered to life as purely academic research soon could turn into a medication that helps people with the rare disease featured in the 1992 movie “Lorenzo’s Oil.”Research published online in the journal Endocrinology found that a small synthetic molecule initially developed to lower cholesterol may slow or stop the devastating progression of the neurodegenerative disease adrenoleukodystrophy, or ALD. The study was conducted in a mouse model, but planning is under way for a human clinical trial. Read more.
Schultz group publishes new paper in Cell Chemical Biology "High-Content Imaging Platform for Profiling Intracellular Signaling Network Activity in Living Cells"
OHSU Scientists Received Funding to Develop a Therapy for a Rare Cancer
Dr. Xiangshu Xiao and his team were recently awarded a new grant from the Elsa U. Pardee Foundation to develop a new therapy for Clear Cell Sarcoma of Soft Tissue or CCSST for short. CCSST is a rare and aggressive cancer. Once the tumor is metastasized, the 5-year survival rate is only 20%. This disease mainly affects adolescents and young adults. CCSST is caused and maintained by a specific gene fusion called EWS-ATF1. While the cause was identified more than two decades ago, no effective therapy is currently available. Dr. Xiao and his team recently developed potent small molecule drugs that inhibit ATF1. With this grant, his team will now investigate the antitumor activity of these inhibitors. Dr. Xiao believes this approach may lead to an effective therapy for this devastating disease.
Researchers develop NAD+ biosensor
Michael Cohen, Ph.D., associate professor of physiology and pharmacology in the OHSU School of Medicine, provided the key insight for this paper by recognizing that a bacterial enzyme, DNA ligase, underwent a significant structural change upon binding to NAD+.